Vaccine Adjuvants

We at SPI are actively expanding our influence in the vaccine adjuvants field. Our strategic growth includes executing significant expansion in the vaccine adjuvant technology market and making substantial investments to enhance our capabilities.

SPI Pharma partners with Q-Vant Biosciences and Inimmune to strengthen our leadership in vaccine adjuvant solutions. With Q-Vant’s sustainable saponin extraction technology and Inimmune’s expertise in novel small molecule adjuvants and delivery systems, we combine innovation, quality, and global reach to provide scalable, high-purity, and next-generation adjuvant solutions for the pharmaceutical industry.